Literature DB >> 32241072

[Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019].

T Zhang1, L X Sun2, R E Feng3.   

Abstract

Severe acute respiratory syndrome (SARS) and coronavirus disease 2019 (COVID-19) shared similar pathogenetic, clinical and pathological features. Fever and cough were the most common symptoms of both diseases, while myalgia and diarrhea were less common in patients with COVID-19. Acute respiratory distress syndrome (ARDS) was the most severe pulmonary complication that caused high mortality rate. Histologically, diffuse alveolar damage (DAD) was the most characteristic finding in non-survivors with either SARS or COVID-19. Cases of patients died less than 10-14 days of disease duration demonstrated acute-phase DAD, while cases beyond 10-14 days of disease duration exhibited organizing-phase DAD in SARS. Meanwhile, organization and fibrosis were usually accompanied by exudation. Coronavirus was mostly detected in pneumocytes, but less in macrophages and bronchiolar epithelial cells. Hemorrhagic necrosis and lymphocyte depletion were found in lymph nodes and spleen in both SARS and COVID-19, indicating a pathological basis of lymphocytopenia. Thrombosis was commonly observed in small vessels and microvasculaturr in lungs accompanying DAD. Microthrombosis was also found in extrapulmonary organs in COVID-19, that was less reported in SARS. Damages in multiple extrapulmonary organs were observed, but coronavirus was not detected in some of those organs, indicating an alternative mechanism beyond viral infection, such as hypoxemia, ischemia and cytokine storm induced immunological injury. DAD due to viral infection and immunological injury, as well as multi-organ dysfunction and extensive microthrombus formation, brought huge challenge to the management of patients with severe SARS or COVID-19.

Entities:  

Keywords:  Coronavirus disease 2019; Diffuse alveolar damage; Pathology; Severe acute respiratory syndrome

Mesh:

Year:  2020        PMID: 32241072     DOI: 10.3760/cma.j.cn112147-20200311-00312

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  42 in total

1.  Thromboembolic events in patients with SARS-CoV-2.

Authors:  Jun Jie Ng; Andrew M T L Choong
Journal:  J Vasc Surg       Date:  2020-04-30       Impact factor: 4.268

Review 2.  PI3K Signaling in Mechanisms and Treatments of Pulmonary Fibrosis Following Sepsis and Acute Lung Injury.

Authors:  Jean Piero Margaria; Lucia Moretta; Jose Carlos Alves-Filho; Emilio Hirsch
Journal:  Biomedicines       Date:  2022-03-23

3.  Exposure modality influences viral kinetics but not respiratory outcome of COVID-19 in multiple nonhuman primate species.

Authors:  Alyssa C Fears; Brandon J Beddingfield; Nicole R Chirichella; Nadia Slisarenko; Stephanie Z Killeen; Rachel K Redmann; Kelly Goff; Skye Spencer; Breanna Picou; Nadia Golden; Cecily C Midkiff; Duane J Bush; Luis M Branco; Matthew L Boisen; Hongmei Gao; David C Montefiori; Robert V Blair; Lara A Doyle-Meyers; Kasi Russell-Lodrigue; Nicholas J Maness; Chad J Roy
Journal:  PLoS Pathog       Date:  2022-07-05       Impact factor: 7.464

4.  Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?

Authors:  Eleni E Ladikou; Helena Sivaloganathan; Kate M Milne; William E Arter; Roshan Ramasamy; Ramy Saad; Simon M Stoneham; Barbara Philips; Alice C Eziefula; Timothy Chevassut
Journal:  Clin Med (Lond)       Date:  2020-07-21       Impact factor: 2.659

5.  Coronavirus Disease 2019: COSeSco - A Risk Assessment Score to Predict the Risk of Pulmonary Sequelae in COVID-19 Patients.

Authors:  Marina Aiello; Laura Marchi; Luigino Calzetta; Silvia Speroni; Annalisa Frizzelli; Marianna Ghirardini; Valentina Celiberti; Nicola Sverzellati; Maria Majori; Pier Anselmo Mori; Silvia Ranzieri; Roberta Pisi; Giovanna Pelà; Massimo Corradi; Alfredo Chetta
Journal:  Respiration       Date:  2021-10-21       Impact factor: 3.966

6.  Functional and Radiological Improvement in a COVID-19 Pneumonia Patient Treated With Steroids.

Authors:  Rahul Singh; Dominic Gaziano
Journal:  Cureus       Date:  2021-05-26

Review 7.  Thrombosis risk associated with COVID-19 infection. A scoping review.

Authors:  Fatimah Al-Ani; Samer Chehade; Alejandro Lazo-Langner
Journal:  Thromb Res       Date:  2020-05-27       Impact factor: 3.944

Review 8.  The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management.

Authors:  Mouhamed Yazan Abou-Ismail; Akiva Diamond; Sargam Kapoor; Yasmin Arafah; Lalitha Nayak
Journal:  Thromb Res       Date:  2020-06-20       Impact factor: 3.944

9.  COVID-19 mortality in patients on anticoagulants and antiplatelet agents.

Authors:  Helena Sivaloganathan; Eleni E Ladikou; Timothy Chevassut
Journal:  Br J Haematol       Date:  2020-07-19       Impact factor: 8.615

Review 10.  Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).

Authors:  Arno R Bourgonje; Amaal E Abdulle; Wim Timens; Jan-Luuk Hillebrands; Gerjan J Navis; Sanne J Gordijn; Marieke C Bolling; Gerard Dijkstra; Adriaan A Voors; Albert Dme Osterhaus; Peter Hj van der Voort; Douwe J Mulder; Harry van Goor
Journal:  J Pathol       Date:  2020-06-10       Impact factor: 9.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.